Vietnam Pharmaceutical Market Outlook to 2027

The Vietnam Pharmaceutical Market is estimated at USD 7,700 Mn in 2024 , and 2024 is the base year for this report. The market is measured on a domestic-consumption basis at manufacturer or ex-factory prices, inclusive of prescription medicines, OTC products, vaccines, and biologics, while excluding medical devices and diagnostics. This matters because it gives investors a cleaner view of revenue actually booked in the pharmaceutical value chain, rather than patient out-of-pocket retail markups or broader healthcare spend that can distort strategy conclusions.

The Vietnam Pharmaceutical Market is projected to reach approximately USD 12,226 Mn by 2030 , implying an 8.0% CAGR for 2025-2030 . This is slower than the historical 9.6% CAGR during 2019-2024 , but still strong for a market of this size. The moderation reflects a higher base, persistent public tender price discipline, and import exposure in specialty therapies. At the same time, the outlook is supported by expanding insurance-backed demand, greater chronic-disease treatment intensity, and premiumization in oncology, vaccines, and biologics.

Profit pools are shifting toward high-value, lower-volume categories and away from purely commoditized volume playbooks. Generic Drugs remain the largest segment at 35.0% of market value in 2024 , but the fastest expansion is in Oncology & Specialty Drugs at 13.5% CAGR . That means a larger share of future value creation should come from specialized hospital access, better regulatory capability, and manufacturing quality upgrades, rather than branch-count expansion alone. Vaccines, biologics, and chronic-care therapies also gain importance because they improve average revenue per unit and support longer treatment pathways.

The main structural risk is the combination of high ETC dependence and continued import exposure in complex therapies and inputs. About 76% of market revenue in 2024 is linked to the prescription-led ETC channel, which means tender pricing, reimbursement rules, and procurement timing can materially affect revenue realization. At the same time, pharmaceutical imports reached nearly USD 1,997.99 Mn in H1 2024 , showing that high-value products and raw materials are still exposed to foreign-exchange and global supply-chain volatility. Margin protection therefore requires both local execution and sourcing resilience.

On the peer set used in this report, Vietnam ranks second by market size after Indonesia and ahead of Thailand, the Philippines, and Malaysia. Its relative strength comes from a favorable balance of scale and growth: the market is already large at USD 7,700 Mn in 2024 , yet it still supports an 8.0% CAGR through 2030 . Vietnam’s position is further reinforced by its insured population base, large domestic manufacturing footprint in generics, and faster mix migration toward specialty therapies than several nearby comparables. This gives it stronger medium-term strategic relevance than a simple income-level comparison would suggest.

The most important long-term driver is the interaction between insurance-backed access and chronic-disease burden. Health insurance already covered 94.2% of the population in 2024 , while Vietnam’s population reached 101.1 million and the share aged 60+ rose to 14.0% . These conditions increase the frequency and duration of medication use, especially in cardiovascular, metabolic, diabetes, respiratory, and oncology categories. In practical terms, that creates a more recurring and clinically anchored revenue base than consumer-health-only markets, which tend to be more discretionary and promotion-sensitive.